Brief: HLS Therapeutics Announces The Sale Of Its Xenpozyme Royalty Interest To DRI Healthcare Trust
02/07/2024 12:09
July 2 (Reuters) - HLS Therapeutics Inc HLS.TO :
* HLS THERAPEUTICS ANNOUNCES THE SALE OF ITS XENPOZYME®
ROYALTY
INTEREST TO DRI HEALTHCARE TRUST
* HLS THERAPEUTICS INC: TOTAL CONSIDERATION OF UP TO $45.75
MILLION
* HLS THERAPEUTICS INC - TO USE UPFRONT CASH TO PAY DOWN
DEBT
* HLS THERAPEUTICS INC - LOWERS 2024 ROYALTY REVENUE
GUIDANCE TO
$1.5 TO $1.7 MILLION
* HLS THERAPEUTICS INC - UPDATES 2024 TOTAL REVENUE GUIDANCE
TO
$58.5 TO $59.7 MILLION
Source text for Eikon: ID:nCNW4N9h2a
Further company coverage: HLS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HLS Therapeutics
See all newsCanada Research Roundup: CIBC ,HLS Therapeutics, TD Bank Group
Canada's HLS Therapeutics Q1 revenue rises on Vascepa growth, reaffirms 2026 guidance
Canada's HLS Therapeutics Q4 revenue slightly beats on Vascepa strength
Brief: Esperion Partner announces HLS Therapeutics received approval Of NILEMDO for the reduction of LDL-cholesterol in canadians at risk of cardiovascular disease
Brief: HLS Therapeutics announces Health Canada approval of NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease